Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity

@inproceedings{Kosmaczewska2014LowDoseIT,
  title={Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity},
  author={Agata Kosmaczewska},
  booktitle={International journal of molecular sciences},
  year={2014}
}
For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, suggesting its protective role, when administered at low-doses. The disrupted balance between regulatory and effector T cells (Tregs and Teffs, respectively) is a characteristic of autoimmune diseases, and is dependent on homeostatic cytokines… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 97 references

Beta-cell-specific IL-2 therapy increases islet Foxp3+ Treg and suppresses type 1 diabetes in NOD mice

  • M. C. Johnson, A. L. Garland, +4 authors R. Tisch
  • Diabetes 2013,
  • 2013
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…